CSL Behring files for MAA of haemophilia B gene therapy
CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
Argenx SE to raise 637m
/in News/by Thomas GabrielczykDutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
Bayer invests into synthetic TCRs for cell therapy
/in News/by Thomas GabrielczykTCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Switzerland paves the way for genome editing
/in News/by Thomas GabrielczykSwitzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.
Gilde Healthcare Private Equity IV launches 517m
/in News/by Thomas GabrielczykGilde Healthcare Private Equity IV (GHPE IV) has closed at 517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.
Precirix NV raises 80m in Series B financing
/in News/by Thomas GabrielczykWith 80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals.
Sanofi bags 300m from US investor Blackstone
/in News/by Thomas GabrielczykSanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.
Join 900 US CEOs protest against Ukraine invasion
/in News/by Thomas GabrielczykUS Life Science leaders pledge to economically disengage from Russia.
Join 900 US CEOs protest against Ukraine war
/in News/by Thomas GabrielczykUS Life Science leaders pledge to economically disengage from Russia.
Scenic Biotech BV announces $31m financing
/in News/by Thomas GabrielczykScenic Biotech BV will use an incoming $31m (28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease. ·